BNP PARIBAS FINANCIAL MARKETS - CATALYST PHARMACEUTICALS INC ownership

CATALYST PHARMACEUTICALS INC's ticker is CPRX and the CUSIP is 14888U101. A total of 254 filers reported holding CATALYST PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.94 and the average weighting 0.1%.

Quarter-by-quarter ownership
BNP PARIBAS FINANCIAL MARKETS ownership history of CATALYST PHARMACEUTICALS INC
ValueSharesWeighting
Q3 2023$2,115,060
-19.7%
180,929
-7.7%
0.00%0.0%
Q2 2023$2,634,616
-63.0%
196,028
-54.3%
0.00%
-70.0%
Q1 2023$7,117,844
+39.9%
429,303
+56.9%
0.01%
+25.0%
Q4 2022$5,087,807
-99.9%
273,538
-3.0%
0.01%
+33.3%
Q3 2022$3,618,278,000
+1574.4%
282,017
+814.9%
0.01%
Q2 2022$216,090,000
-2.9%
30,826
+14.8%
0.00%
Q1 2022$222,653,000
-39.1%
26,858
-50.3%
0.00%
-100.0%
Q4 2021$365,587,000
+167.0%
54,001
+109.0%
0.00%
Q3 2021$136,936,000
+64.9%
25,837
+78.9%
0.00%
Q2 2021$83,064,000
-39.0%
14,446
-51.1%
0.00%
Q1 2021$136,207,000
+152.7%
29,546
+83.1%
0.00%
Q4 2020$53,908,000
-29.5%
16,140
-37.3%
0.00%
Q3 2020$76,415,000
-11.9%
25,729
+37.0%
0.00%
Q2 2020$86,777,000
-72.3%
18,783
-76.9%
0.00%
-100.0%
Q1 2020$313,417,000
+632.7%
81,407
+613.7%
0.00%
Q4 2019$42,776,000
-47.3%
11,407
-25.4%
0.00%
Q3 2019$81,211,000
+85.5%
15,294
+34.2%
0.00%
Q2 2019$43,768,000
-57.2%
11,398
-43.1%
0.00%
Q1 2019$102,214,000
+764.5%
20,042
+540.7%
0.00%
Q3 2018$11,824,000
+21.2%
3,1280.0%0.00%
Q2 2018$9,759,000
-76.8%
3,128
-82.2%
0.00%
Q1 2018$42,107,000
-27.5%
17,618
+18.6%
0.00%
Q4 2017$58,091,000
+230.2%
14,857
+112.8%
0.00%
Q3 2017$17,592,000
-15.0%
6,981
-6.9%
0.00%
Q2 2017$20,694,000
-44.5%
7,498
-50.7%
0.00%
Q4 2015$37,254,000
-18.5%
15,206
-0.2%
0.00%
Q3 2015$45,687,000
+76.5%
15,229
+143.0%
0.00%
Q2 2015$25,883,0006,2670.00%
Other shareholders
CATALYST PHARMACEUTICALS INC shareholders Q3 2023
NameSharesValueWeighting ↓
TANAKA CAPITAL MANAGEMENT INC 148,281$2,4587.14%
GABLES CAPITAL MANAGEMENT INC. 409,080$6,782,5464.74%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 10,355,099$171,687,5413.83%
JW Asset Management, LLC 563,392$9,341,0393.58%
Quantedge Capital Pte Ltd 324,700$5,383,5262.10%
Paradiem, LLC 236,628$3,923,2921.22%
SummerHaven Investment Management, LLC 100,592$1,667,8150.97%
Capital Impact Advisors, LLC 46,096$764,2720.94%
Yorktown Management & Research Co Inc 50,000$829,0000.89%
Seaport Global Advisors, LLC 15,598$258,6150.82%
View complete list of CATALYST PHARMACEUTICALS INC shareholders